Concepedia

Author

Ferdinando Frigeri

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"ORCID

Also Known As

F Frigeri, F. Frigeri, Ferdinando Frigeri, Miriana Ruggieri

110

Publications

1.9K

Citations

22

H-Index

42

Concepts

All Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Federico II University HospitalUniversity of Naples Federico IICeinge Biotecnologie Avanzate (Italy)Ospedale Antonio Cardarelli
FF

About

Ferdinando Frigeri is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in medicine, immunology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

12

379

2

Immunology

9

9

309

3

Cell Biology

5

5

125

4

Hepatology

1

1

12

5

Molecular Genetics

1

1

20

Ferdinando Frigeri

×

29

Publications

1.4K

Citations

19

H-Index

YearCitations

Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) [see comments]

Fabrizio Pane, Ferdinando Frigeri, M Sindona,

Blood

1996

387

<sup>90</sup>Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial

Christian W. Scholz, Werner Linkesch, Ola Lindén,

Journal of Clinical Oncology

2012

108

Consistent amounts of acute leukemia-associated P190BCR/ABL transcripts are expressed by chronic myelogenous leukemia patients at diagnosis

Giuseppe Saglio, Fabrizio Pane, Enrico Gottardi,

Blood

1996

104

RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphoma

Gaetano Corazzelli, Ferdinando Frigeri, Filippo Russo,

British Journal of Haematology

2011

76

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone,

Cancer Chemotherapy and Pharmacology

2009

75

Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study

Daniele Laszlò, Giovanna Andreola, Luigi Rigacci,

Journal of Clinical Oncology

2010

60

Biweekly rituximab, cyclophosphamide, vincristine, non‐pegylated liposome‐encapsulated doxorubicin and prednisone (R‐COMP‐14) in elderly patients with poor‐risk diffuse large B‐cell lymphoma and moderate to high ‘life threat’ impact cardiopathy

Gaetano Corazzelli, Ferdinando Frigeri, Manuela Arcamone,

British Journal of Haematology

2011

58

HCV and cancer: a case‐control study in a high‐endemic area

Maurizio Montella, Anna Crispo, Giovanna de Bellis,

Liver International

2001

58

HCV and tumors correlated with immune system: a case-control study in an area of hyperendemicity

Maurizio Montella, Anna Crispo, Ferdinando Frigeri,

Leukemia Research

2001

48

Rapid Reversion of Loeffler's Endocarditis by Imatinib in Early Stage Clonal Hypereosinophilic Syndrome

Bruno Rotoli, Lucio Catalano, Maurizio Galderisi,

Leukemia & lymphoma/Leukemia and lymphoma

2004

43

Page 1